These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19103739)

  • 21. [Treatment of secondary hyperparathyroidism in renal insufficiency: role of calcitriol, sevelamer and cinacalcet].
    Bonny O; Burnier M
    Rev Med Suisse; 2008 Mar; 4(147):589-92, 594-5. PubMed ID: 18402017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of cinacalcet in the treatment of CKD-MBD].
    Koiwa F; Maruta Y
    Clin Calcium; 2010 Jul; 20(7):1089-95. PubMed ID: 20585188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride.
    Sumida K; Nakamura M; Ubara Y; Marui Y; Tanaka K; Takaichi K; Tomikawa S; Inoshita N; Ohashi K
    J Clin Pathol; 2011 Sep; 64(9):756-60. PubMed ID: 21565858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cinacalcet hydrochloride in chronic kidney disease-mineral bone disorder.
    Yokoyama K
    Clin J Am Soc Nephrol; 2009 Sep; 4(9):1405-8. PubMed ID: 19696214
    [No Abstract]   [Full Text] [Related]  

  • 25. Calcimimetics, calcium set point and calcium balance.
    Giotta N; Marino A
    Nephrol Dial Transplant; 2008 Dec; 23(12):4083-4. PubMed ID: 18728157
    [No Abstract]   [Full Text] [Related]  

  • 26. Cost-utility analysis of cinacalcet in addition to standard of care in the UK.
    Ray JA; Valentine WJ; Palmer AJ
    Nephrol Dial Transplant; 2007 Nov; 22(11):3355-7; author reply 3357-8. PubMed ID: 17785347
    [No Abstract]   [Full Text] [Related]  

  • 27. Fooling the parathyroid gland--will there be health benefits?
    Curhan G
    N Engl J Med; 2004 Apr; 350(15):1565-7. PubMed ID: 15071132
    [No Abstract]   [Full Text] [Related]  

  • 28. [Progress in the treatment of secondary hyperparathyroidism. Role of calcimimetics].
    Sułowicz W
    Przegl Lek; 2006; 63 Suppl 3():3-9. PubMed ID: 16898475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New insights into the role of calcium-sensing receptor activation.
    Cozzolino M; Mazzaferro S; Messa P
    J Nephrol; 2011; 24 Suppl 18():S38-41. PubMed ID: 21623581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Parathyroid and bone. Calcimimetics and bone metabolism].
    Fukumoto S
    Clin Calcium; 2007 Dec; 17(12):1865-9. PubMed ID: 18057662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of ultrasound to assess the response to therapy for secondary hyperparathyroidism.
    Meola M; Petrucci I; Colombini E; Barsotti G
    Am J Kidney Dis; 2011 Sep; 58(3):485-91. PubMed ID: 21715073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cinacalcet cost and utility in dialysis patients.
    Cohen E; Uribarri J
    Semin Dial; 2005; 18(4):353-4. PubMed ID: 16076364
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical application of calcimimetics].
    Nishi H; Fukagawa M
    Clin Calcium; 2004 May; 14(5):756-9. PubMed ID: 15577038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy.
    Strippoli GF; Palmer S; Tong A; Elder G; Messa P; Craig JC
    Am J Kidney Dis; 2006 May; 47(5):715-26. PubMed ID: 16632010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Kidney and bone update : the 5-year history and future of CKD-MBD. Parathyroidectomy for secondary hyperparathyroidism].
    Tominaga Y
    Clin Calcium; 2012 Jul; 22(7):1083-8. PubMed ID: 22750941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regression of vascular calcification in a patient treated with cinacalcet: a case report.
    Salgueira M; Martínez AI; Milán JA
    Nefrologia; 2011; 31(5):602-6. PubMed ID: 21959728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is it worth correcting hyperparathyroidism if hyperphosphatemia and hypocalcemia worsen? A cinacalcet story.
    Kalantar-Zadeh K; Kovesdy CP
    Am J Kidney Dis; 2009 Feb; 53(2):183-8. PubMed ID: 19166796
    [No Abstract]   [Full Text] [Related]  

  • 38. Cinacalcet in hyperfunctioning parathyroid diseases.
    Imanishi Y; Inaba M; Kawata T; Nishizawa Y
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S7-S11. PubMed ID: 19765257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calcium, calcimimetics and clinical outcomes.
    Block G
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):170-1. PubMed ID: 17699205
    [No Abstract]   [Full Text] [Related]  

  • 40. Cinacalcet for secondary hyperparathyroidism in hemodialysis recipients.
    Owda AK; Alam MG; Kumar J
    N Engl J Med; 2004 Jul; 351(2):188-9; author reply 188-9. PubMed ID: 15247361
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.